ImmunoScape
PrivateLast Round
Strategic
Mar 4, 2026
Est. Valuation
$37.9M
Total Funding Raised
$39M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ImmunoScape is a biotechnology company that discovers and develops next-generation T-cell receptor (TCR) cell therapies in the field of oncology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Government Contracts
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ImmunoScape Comparables
Compare ImmunoScape with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Lion TCR | 86% | |
| BlueSphere Bio | 84% | |
| 3T Biosciences | 83% | |
ImmunoScape Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Mar 4, 2026 | ||||
| Series B Extension | Sep 20, 2022 | ||||
| Series A Extension | Apr 14, 2021 | ||||
| Series A | Aug 12, 2020 |
Key People
Founding team and executive leadership
ImmunoScape Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| UTEC (The University of Tokyo Edge Capital Partners) | Series A, Series A Extension |
| EDBI | Series B Extension, Series A Extension |
| Amgen Ventures | Series B Extension |
| Anzu Partners | Series B Extension, Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 16, 2026
Partnering to develop a breakthrough cell therapy for solid tumors.
- Mar 4, 2026
Leonardo DiCaprio participated in the round.
ImmunoScape Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about ImmunoScape's valuation, stock price, and market status.